Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Retained Earnings (2016 - 2025)

Seres Therapeutics' Retained Earnings history spans 11 years, with the latest figure at -$957.1 million for Q3 2025.

  • For Q3 2025, Retained Earnings changed N/A year-over-year to -$957.1 million; the TTM value through Sep 2025 reached -$957.1 million, changed N/A, while the annual FY2024 figure was -$978.1 million, 0.01% changed from the prior year.
  • Retained Earnings for Q3 2025 was -$957.1 million at Seres Therapeutics, up from -$965.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$12000.0 in Q4 2022 and bottomed at -$1.0 billion in Q1 2024.
  • The 5-year median for Retained Earnings is -$842.4 million (2022), against an average of -$766.6 million.
  • The largest annual shift saw Retained Earnings tumbled 63257200.0% in 2021 before it surged 100.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$614.4 million in 2021, then soared by 100.0% to -$12000.0 in 2022, then tumbled by 8151858.33% to -$978.2 million in 2023, then increased by 0.01% to -$978.1 million in 2024, then increased by 2.15% to -$957.1 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Retained Earnings are -$957.1 million (Q3 2025), -$965.3 million (Q2 2025), and -$945.4 million (Q1 2025).